PRA International Announces Collaboration with Frontage Laboratories
News Dec 05, 2008
PRA International has announced a collaborative agreement with Frontage Laboratories Inc. This partnership enables PRA Early Development Services’ US Clinical Pharmacology Center (PRA EDS US CPC) to now offer a full complement of analytical lab testing services to its existing Phase I – IV clinical trial services in North America.
PRA’s 80-bed Lenexa clinical facility near Kansas City, Missouri, runs a multitude of Phase I and Phase IIa studies each year, with a particular focus on first in human studies and other complex PK studies.
By meaningfully broadening its bioanalytical service portfolio, PRA now offers Pharma and Biotech sponsors and other CROs the ability to align the clinical and laboratory processes. It already operates a comparable full-service offering in Europe.
Although PRA conducts clinical trials across a broad spectrum of therapeutic areas, it has a special emphasis in the areas of oncology, central nervous system, allergy/respiratory, cardiovascular disorders and infectious diseases.
Frontage Laboratories Inc. is fully compliant with cGMP/GLP regulations and under this new collaboration will offer specialized bioanalytical services via PRA. The new collaboration also offers pharmacokinetic & biostatistical consultancy and data support.
XenoGesis and BioAscent Forge Alliance to Offer Enhanced Integrated Drug Discovery ServicesNews
XenoGesis and BioAscent Discovery Limited have announced a collaboration to offer an enhanced range of integrated drug discovery services, including medicinal chemistry, biology and DMPK.READ MORE
BioAscent Establishes Integrated Drug Discovery Services OfferingNews
Dr Phil Jones to join as new CSO to lead company’s extended capabilities in medicinal chemistry and in vitro biosciences.READ MORE
Lab Innovations returns to the NEC, Bimingham , UKNews
Save the date for the UK’s only lab-dedicated exhibition showcase!READ MORE
Comments | 0 ADD COMMENT
International Conference on Biobetters and Regulatory Affairs
Jun 27 - Jun 28, 2018